Jan Hau Lee1, Yoke Hwee Chan, Oi Fah Lai, Janil Puthucheary. 1. Children's Intensive Care Unit, Department of Paediatric Subspecialties, KK Women's and Children's Hospital, 100 Bukit Timah Road, Singapore, 229899, Singapore. leejanhau@gmail.com
Abstract
PURPOSE: Levels of vasopressin and its precursor copeptin in pediatric sepsis and septic shock are not well defined. The main aim of this study is to compare the serum levels of vasopressin and copeptin in children with septic shock or sepsis and in healthy children. We hypothesized that vasopressin and copeptin levels are elevated in early and late stages of pediatric septic shock. METHODS: Three groups were included: healthy children, children with clinical diagnosis of sepsis, and children admitted to the pediatric intensive care unit (PICU) with diagnosis of sepsis shock. Blood samples were drawn from children in all groups within 24 h of admission. For the septic shock group, additional samples at 24-h intervals were drawn up to 120 h after PICU admission. We used competitive immunoassays to determine vasopressin and copeptin levels. RESULTS: There were 70 children in the control group, 53 children in the sepsis group, and 13 in the septic shock group. At baseline, there was a difference in median vasopressin levels [60.9 (Interquartile range: 32.3, 138.0) vs. 141.1 (45.2, 542) vs. 326 (55.6, 399) pg/mL, p < 0.05], but there was no difference in copeptin levels [1.2 (0.8, 1.8) vs. 1.5 (1.0, 2.2) vs. 0.9 (0.8, 1.2) ng/mL, p = 0.14] between the three groups. There was no difference in vasopressin and copeptin levels in early and late stages of pediatric septic shock. CONCLUSIONS: Baseline vasopressin levels were different between the three groups. In pediatric septic shock, vasopressin and copeptin levels are not robust markers for severity and clinical outcomes.
PURPOSE: Levels of vasopressin and its precursor copeptin in pediatric sepsis and septic shock are not well defined. The main aim of this study is to compare the serum levels of vasopressin and copeptin in children with septic shock or sepsis and in healthy children. We hypothesized that vasopressin and copeptin levels are elevated in early and late stages of pediatric septic shock. METHODS: Three groups were included: healthy children, children with clinical diagnosis of sepsis, and children admitted to the pediatric intensive care unit (PICU) with diagnosis of sepsis shock. Blood samples were drawn from children in all groups within 24 h of admission. For the septic shock group, additional samples at 24-h intervals were drawn up to 120 h after PICU admission. We used competitive immunoassays to determine vasopressin and copeptin levels. RESULTS: There were 70 children in the control group, 53 children in the sepsis group, and 13 in the septic shock group. At baseline, there was a difference in median vasopressin levels [60.9 (Interquartile range: 32.3, 138.0) vs. 141.1 (45.2, 542) vs. 326 (55.6, 399) pg/mL, p < 0.05], but there was no difference in copeptin levels [1.2 (0.8, 1.8) vs. 1.5 (1.0, 2.2) vs. 0.9 (0.8, 1.2) ng/mL, p = 0.14] between the three groups. There was no difference in vasopressin and copeptin levels in early and late stages of pediatric septic shock. CONCLUSIONS: Baseline vasopressin levels were different between the three groups. In pediatric septic shock, vasopressin and copeptin levels are not robust markers for severity and clinical outcomes.
Authors: Stefan Jochberger; Nils G Morgenthaler; Viktoria D Mayr; Günter Luckner; Volker Wenzel; Hanno Ulmer; Siegfried Schwarz; Walter R Hasibeder; Barbara E Friesenecker; Martin W Dünser Journal: J Clin Endocrinol Metab Date: 2006-08-29 Impact factor: 5.958
Authors: Tarek Sharshar; Robert Carlier; Anne Blanchard; Antoine Feydy; Françoise Gray; Michel Paillard; Jean-Claude Raphael; Philippe Gajdos; Djillaii Annane Journal: Crit Care Med Date: 2002-03 Impact factor: 7.598
Authors: Stefan Jochberger; Viktoria D Mayr; Günter Luckner; Volker Wenzel; Hanno Ulmer; Stefan Schmid; Hans Knotzer; Werner Pajk; Walter Hasibeder; Barbara Friesenecker; Andreas J Mayr; Martin W Dünser Journal: Crit Care Med Date: 2006-02 Impact factor: 7.598
Authors: D R Repaske; R Medlej; E K Gültekin; M R Krishnamani; G Halaby; J W Findling; J A Phillips Journal: J Clin Endocrinol Metab Date: 1997-01 Impact factor: 5.958
Authors: Karen Choong; Desmond Bohn; Douglas D Fraser; Isabelle Gaboury; James S Hutchison; Ari R Joffe; Catherine Litalien; Kusum Menon; Patrick McNamara; Roxanne E Ward Journal: Am J Respir Crit Care Med Date: 2009-07-16 Impact factor: 21.405
Authors: Stefan Jochberger; Matthias Zitt; Günter Luckner; Viktoria D Mayr; Volker Wenzel; Hanno Ulmer; Nils G Morgenthaler; Walter R Hasibeder; Martin W Dünser Journal: Shock Date: 2009-02 Impact factor: 3.454
Authors: Michael G Gaies; James G Gurney; Alberta H Yen; Michelle L Napoli; Robert J Gajarski; Richard G Ohye; John R Charpie; Jennifer C Hirsch Journal: Pediatr Crit Care Med Date: 2010-03 Impact factor: 3.624
Authors: Giuseppe Citerio; Jan Bakker; Matteo Bassetti; Dominique Benoit; Maurizio Cecconi; J Randall Curtis; Glenn Hernandez; Margaret Herridge; Samir Jaber; Michael Joannidis; Laurent Papazian; Mark Peters; Pierre Singer; Martin Smith; Marcio Soares; Antoni Torres; Antoine Vieillard-Baron; Jean-François Timsit; Elie Azoulay Journal: Intensive Care Med Date: 2013-12-13 Impact factor: 17.440
Authors: Benjamin Stöcklin; Sotirios Fouzas; Paula Schillinger; Sevgi Cayir; Roswitha Skendaj; Michel Ramser; Peter Weber; Sven Wellmann Journal: PLoS One Date: 2015-04-20 Impact factor: 3.240